medigraphic.com
ISSN 2683-1678 (Print)
Órgano Oficial de la Sociedad
Latinoamericana de lnfectología Pediátrica.
Órgano de la Asociación Mexicana de
Infectología Pediátrica, A.C.
Órgano difusor de la Sociedad Española
de lnfectología

2018, Number 3

<< Back Next >>

Rev Latin Infect Pediatr 2018; 31 (3)

Dengue surveillance in children who received CYD tetravalent dengue vaccine during their second year of life while participating in a clinical trial in a southern state of Mexico

Arredondo-García JL, Rodríguez MFI, Sosa CZP, Sosa BGC, Sansores RAJ

Language: English
References: 13
Page: 104-109
PDF size: 192.49 Kb.


ABSTRACT

Dengue is a systemic viral infection transmitted to humans by mosquitoes and is a public health challenge due to its rapid global expansion and lack of specific therapeutic agents. To date (January 2018), the CYD-TDV vaccine has been granted licensure in 19 countries. The World Health Organization global strategy for dengue prevention and control 2012-2020 has, as a global goal, the reduction of the burden of disease. One of the technical elements of this strategy is the implementation of a dengue vaccine. This is an epidemiological descriptive study of 248 subjects with retrospective and passive surveillance for 2 years; from this cohort, 162 subjects, ages 4 years 8 months to 5 years 9 months, underwent active surveillance. Eligible participants were children who participated in the previous randomized phase III trial conducted in Merida, Yucatan, Mexico. All the subjects who completed the previous trial were included for retrospective/passive surveillance; the subjects who underwent active surveillance (n = 162 subjects) were identified during a three-month enrollment period. Blood draws and phone calls (study procedures) were performed under the applicable local and international regulations. None of the 248 participants followed for passive surveillance had a reported confirmed dengue case. Forty-one cases of suspected vector-transmitted disease without virological or serological confirmation were detected. The result of this study provides support for the safety of the vaccine in this age group. Further follow-ups in similar populations should be done in order to obtain more information.


REFERENCES

  1. Simmons CP, Farrar JJ, Nguyen VV, Wills B. Dengue. N Engl J Med. 2012; 366: 1423-1432.

  2. World Health Organization. Dengue control. Epidemiology, Geneva, Switzerland. [Accessed July 31, 2017] Available at: http://www.who.int/denguecontrol/epidemiology/en/.

  3. World Health Organization. Global strategy for dengue prevention and control, 2012-2020. Geneva: Publications of the World Health Organization; 2012. Available at: http://apps.who.int/iris/bitstream/10665/75303/1/9789241504034_eng.pdf?ua=1. Accessed May 25, 2014.

  4. La Ruche G, Souarès Y, Armengaud A, Peloux-Petiot F, Delaunay P, Desprès P et al. First two autochthonous dengue virus infections in metropolitan France, September 2010. Euro Surveill. 2010; 15 (39): 19676.

  5. Melo FIR, Morales JJR, De Los Santos AHM, Rivas E, Vigne C, Noriega F. Immunogenicity and safety of a booster injection of DTap-IPV//Hib (Pentaxim) administered concomitantly with tetravalent dengue vaccine in healthy toddlers 15-18 months of age in Mexico: a randomized trial. Pediatr Infect Dis J. 2017; 36 (6): 602-608.

  6. Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, Chua MN et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014; 384 (9951): 1358-1365.

  7. Villar L, Dayan GH, Arredondo-García JL, Rivera DM, Cunha R, Deseda C et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med. 2015; 372: 113-123.

  8. Hadinegoro SR, Arredondo-García JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med. 2015; 373 (13): 1195-1206.

  9. Secretaría de Salud. Panorama epidemiológico de dengue, 2017, México. 2017. [Accessed 1 Jan 2018] Available at: https://www.gob.mx/cms/uploads/attachment/file/285237/Pano_dengue_sem_52_201 7.pdf.

  10. Secretaría de Salud. Dirección General de Información en Salud. Cubos Dinámicos Egresos Hospitalarios. SAEH 2017. [Accessed 18 Sept 2017] Available at: http://www.dgis.salud.gob.mx/contenidos/basesdedatos/bdc_egresoshosp_gobmx.html

  11. Aguiar M, Stollenwerk N, Halstead SB. The risks behind Dengvaxia recommendation. Lancet Infect Dis. 2016; 16: 882-883.

  12. Pang T. SAGE committee advice on dengue vaccine. Lancet Infect Dis. 2016; 16: 880-882.

  13. World Health Organization. Revised SAGE recommendation on use of dengue vaccine, Geneva. Geneva: WHO; 2018. [Accessed 5 June 2018] Available at: http://www.who.int/immunization/diseases/dengue/revised_SAGE_recommendations_dengue_vaccines_apr2018/en/:




2020     |     www.medigraphic.com